Mr. Douglas M Jermasek is appointed as Vice President of Marketing and Strategy of the Comapny. Effective July 1, 2016. He has more than 20 years of biopharmaceutical strategic marketing experience. Prior to joining Keryx, from 2002 to …
Investors in Keryx Biopharmaceuticals, Inc. KERX need to pay close attention to the stock based on moves in the options market lately. That is because the March 16, 2018 $3.50 Put had some of the highest implied volatility of all equity …
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in …
Investors in Keryx Biopharmaceuticals, Inc. KERX need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 16, 2018 $3.00 Put had some of the highest implied volatility of all equity …
Investors in Keryx Biopharmaceuticals, Inc. KERX need to pay close attention to the stock based on moves in the options market lately. That is because the January 19, 2018 $3 Put had some of the highest implied volatility of all equity …
Mr. Scott A. Holmes serves as a Chief Financial Officer, Treasurer of the Company. Mr. Holmes joined the company from AMAG Pharmaceuticals where he most recently served as Senior Vice President, Finance and Investor Relations …